CD8A and neoplasm: Zerbini et al. [39] demonstrated in vitro induction of CD8+ T-cell responses against previously identified MAGE-A1 and MAGE-A3 epitopes in tumour infiltrating but not peripheral blood lymphocytes derived from HCC patients.